Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dolichol-phosphate mannosyltransferase subunit 2 (DPM2) is a highly hydrophobic, small ER membrane protein that serves as the regulatory subunit of the dolichol-phosphate-mannose (DPM) synthase complex in humans[1][3][4]. This complex is essential for the formation of dolichol-phosphate mannose, a critical glycosyl donor for various glycosylation pathways, including N-glycosylation, O-mannosylation, and GPI-anchor synthesis[1][3][4]. DPM2 anchors and stabilizes the catalytic subunit DPM1 and is essential for maintaining proper localization and activity of the complex within the endoplasmic reticulum, thereby regulating protein and lipid glycosylation[2][4]. Loss-of-function or mutation in DPM2 results in congenital disorders of glycosylation, predominantly affecting muscular and nervous system development and resulting in clinical features such as hypotonia, developmental delay, and abnormal enzyme glycosylation profiles[4]. No known drugs target DPM2 directly, and there are no established mechanisms of action for pharmacological modulation of this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dolichol-phosphate mannosyltransferase subunit 2 (DPM2).